The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Drugs & Targets

FDA accepts Mylan’s BLA for biosimilar pegfilgrastim

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Mylan N.V. and Biocon Ltd. said the FDA has accepted Mylan’s Biologics License Application for MYL-1401H, a proposed biosimilar to Neulasta (pegfilgrastim), for filing through the 351(k) pathway.

The proposed biosimilar to Neulasta is used to reduce the duration of neutropenia (low count of neutrophils, a type of white blood cells) and the incidence of fever associated with neutropenia in adult patients treated with chemotherapy in certain types of cancer. The FDA goal date set under the Biosimilar User Fee Act is Oct. 9.

The proposed biosimilar pegfilgrastim is one of the six biologic products co-developed by Mylan and Biocon for the global marketplace.

Table of Contents

YOU MAY BE INTERESTED IN

PodcastThe Directors

The Directors: Steven Artandi and Eric Winer on how looming policy changes “reverberate” through oncology
“Even when funding gets restored and if the H-1B visa threat doesn’t materialize, it creates an environment where especially young people become uncertain.”

With major leadership changes, grant disruptions and terminations, and a stoked distrust in science, Steven Artandi, the director of Stanford Cancer Center, worries that young investigators will feel disenchanted by the U.S. research atmosphere and take their work and study elsewhere. 
By Claire Marie Porter and Paul Goldberg
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account